Aizawa Toru, Yamauchi Keishi, Yamada Masayuki
Diabetes Center, Aizawa Hospital, 2-5-1 Honjo, Matsumoto, Japan.
Clinical Research Department, Kissei Pharmaceutical, Tokyo, Japan.
Springerplus. 2014 May 20;3:252. doi: 10.1186/2193-1801-3-252. eCollection 2014.
Since there had been no previous studies of alterations in insulin sensitivity, glucose-stimulated insulin secretion, beta cell function and glucose effectiveness during the development of non-diabetic hyperglycemia in Asian populations, we conducted a longitudinal study of such changes in 244 Japanese adults with normal glucose tolerance (median BMI 23.3 kg/m(2) and age 51 yrs). The median follow-up period was 3.3 yrs. One hundred and eighty-two subjects maintained normal glucose tolerance (nonprogressors). After excluding the 3 subjects who progressed to diabetes, we analyzed the 59 who developed non-diabetic hyperglycemia (progressors), of which 31 progressed to impaired fasting glucose and 28 to impaired glucose tolerance. Whole body insulin sensitivity was estimated by ISIMatsuda, glucose-stimulated insulin secretion by [δIRI0-30/δPG0-30] and Stumvoll indices, hepatic insulin sensitivity by quantitative insulin sensitivity check index (QUICKI) and 1/fasting IRI, beta cell function by oral disposition index (DIO) ([δIRI0-30/δPG0-30]∙[ISIMatsuda]), and glucose effectiveness by an OGTT-derived index (SgIO). ISIMatsuda (p <0.05), [δIRI0-30/δPG0-30], DIO and SgIO (both p <0.01), but not QUICKI, 1/fasting IRI, or Stumvoll-1st and -2nd phases, were lower in the progressors at baseline. This group was also characterized by the following: 1) ISIMatsuda, DIO and SgIO were reduced by 34%, 32% and 11%, respectively (all p <0.01); 2) QUICKI and 1/fasting IRI diminished by 21% and 5%, respectively (both p <0.01); and 3) no significant changes were found in [δIRI0-30/δPG0-30], Stumvoll-1st and -2nd phases or BMI during the follow-up. In the nonprogressors, no indices changed significantly during the follow-up. Our study concluded that during the transition from normal glucose tolerance to non-diabetic hyperglycemia in this non-obese population, whole body insulin sensitivity, hepatic insulin sensitivity, beta cell function, and glucose effectiveness were all attenuated, but no significant changes in glucose-stimulated insulin secretion occurred. Also of note is the fact that the transition took place without any accompanying increase in BMI.
由于此前尚无关于亚洲人群非糖尿病性高血糖发展过程中胰岛素敏感性、葡萄糖刺激的胰岛素分泌、β细胞功能和葡萄糖有效性变化的研究,我们对244名糖耐量正常的日本成年人(中位BMI 23.3kg/m²,年龄51岁)进行了此类变化的纵向研究。中位随访期为3.3年。182名受试者维持糖耐量正常(未进展者)。在排除3名进展为糖尿病的受试者后,我们分析了59名发生非糖尿病性高血糖的受试者(进展者),其中31名进展为空腹血糖受损,28名进展为糖耐量受损。通过松田胰岛素敏感性指数(ISIMatsuda)评估全身胰岛素敏感性,通过[δIRI0 - 30/δPG0 - 30]和Stumvoll指数评估葡萄糖刺激的胰岛素分泌,通过定量胰岛素敏感性检查指数(QUICKI)和1/空腹IRI评估肝脏胰岛素敏感性,通过口服处置指数(DIO)([δIRI0 - 30/δPG0 - 30]∙[ISIMatsuda])评估β细胞功能,通过口服葡萄糖耐量试验衍生指数(SgIO)评估葡萄糖有效性。进展者在基线时,ISIMatsuda(p <0.05)、[δIRI0 - 30/δPG0 - 30]、DIO和SgIO(均p <0.01)较低,但QUICKI、1/空腹IRI或Stumvoll第一和第二阶段无差异。该组还具有以下特征:1)ISIMatsuda、DIO和SgIO分别降低了34%、32%和11%(均p <0.01);2)QUICKI和1/空腹IRI分别降低了21%和5%(均p <0.01);3)随访期间[δIRI0 - 30/δPG0 - 30]、Stumvoll第一和第二阶段或BMI无显著变化。在未进展者中,随访期间各项指标均无显著变化。我们的研究得出结论,在这个非肥胖人群从糖耐量正常向非糖尿病性高血糖转变的过程中,全身胰岛素敏感性、肝脏胰岛素敏感性、β细胞功能和葡萄糖有效性均减弱,但葡萄糖刺激的胰岛素分泌无显著变化。同样值得注意的是,这种转变发生时BMI没有任何伴随增加。